Equillium Inc. (NASDAQ: EQ) stock has experienced typical clinical-stage biotechnology volatility, moving through various trading ranges over the past year. Market valuations fluctuate in response to quarterly financial reports, updates on cash burn and operational runways, and clinical trial readouts evaluating its lead therapeutic candidates for severe autoimmune and immunological diseases.